Lisanti Capital Growth LLC Acquires Shares of 30,485 Masimo Corporation (NASDAQ:MASI)

Lisanti Capital Growth LLC purchased a new position in shares of Masimo Corporation (NASDAQ:MASI - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 30,485 shares of the medical equipment provider's stock, valued at approximately $5,079,000. Masimo accounts for about 1.5% of Lisanti Capital Growth LLC's portfolio, making the stock its 20th largest holding. Lisanti Capital Growth LLC owned 0.06% of Masimo as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. FMR LLC raised its holdings in shares of Masimo by 19.8% during the 4th quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock worth $1,338,509,000 after acquiring an additional 1,340,836 shares during the period. Vanguard Group Inc. raised its holdings in shares of Masimo by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider's stock worth $758,182,000 after acquiring an additional 66,215 shares during the period. Capital Research Global Investors raised its holdings in shares of Masimo by 80.5% during the 4th quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock worth $405,807,000 after acquiring an additional 1,094,647 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Masimo by 119.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock worth $286,823,000 after acquiring an additional 943,001 shares during the period. Finally, T. Rowe Price Investment Management Inc. raised its holdings in shares of Masimo by 8.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,662,376 shares of the medical equipment provider's stock worth $274,791,000 after acquiring an additional 135,888 shares during the period. Hedge funds and other institutional investors own 85.96% of the company's stock.

Insider Buying and Selling at Masimo

In other Masimo news, COO Bilal Muhsin sold 10,000 shares of Masimo stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $163.28, for a total value of $1,632,800.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at $3,946,804.16. The trade was a 29.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 9.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on MASI. Wells Fargo & Company reduced their price target on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a report on Thursday, April 10th. BTIG Research set a $193.00 price target on Masimo and gave the stock a "buy" rating in a report on Wednesday, May 7th. Wall Street Zen lowered shares of Masimo from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Finally, Raymond James Financial reduced their price objective on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $191.60.

Masimo Stock Up 0.9%

Shares of MASI opened at $168.21 on Friday. The firm has a market cap of $9.12 billion, a P/E ratio of -18.34 and a beta of 1.19. Masimo Corporation has a 12-month low of $101.61 and a 12-month high of $194.88. The company's 50-day moving average price is $160.72 and its 200 day moving average price is $166.67. The company has a current ratio of 2.17, a quick ratio of 1.62 and a debt-to-equity ratio of 0.67.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.12. The firm had revenue of $372.00 million for the quarter, compared to analyst estimates of $367.79 million. Masimo had a negative net margin of 25.06% and a positive return on equity of 22.56%. Masimo's revenue was down 24.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.77 EPS. On average, sell-side analysts forecast that Masimo Corporation will post 4.1 earnings per share for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Corporation (NASDAQ:MASI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.